Raymond James added Trevi Therapeutics (TRVI) to the firm’s Analyst Current Favorites list. The list contains the current favorite stock ideas from the firm’s equity analysts. An analyst may only have one “buy” idea on the list at any given time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics: Buy Rating Amid Promising Haduvio Trial Prospects and Strong Market Potential
- Trevi Therapeutics (TRVI) Q4 Earnings Cheat Sheet
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer
Questions or Comments about the article? Write to editor@tipranks.com